Clinical Trial - Follow Up Long Term Extension (LTE) Trial was a follow up study to establish the long-term safety of AV-101. Subjects who successfully completed the 24-week placebo-controlled parent trial (NCT#05036135) were offered the opportunity to continue into this LTE study. Sub-jects who enrolled in the study were to re-ceive one of three active AV-101 doses until such time as the optimal dose was selected in the parent study. TERMINATED! The while inhaled imatinib was well tolerated, it did not prove to be efficacious.
